Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Terminated Phase 4 Interventional Results available

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

NCT02661295
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions
Ferric Citrate
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 24, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

NCT00045292
View directory record Official record
Conditions
Cancer
Interventions
acyclovir, acyclovir sodium, valacyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 24, 2026, 6:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

NCT01273181
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
Interventions
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 24, 2026, 6:07 AM EDT
Recruiting No phase listed Observational

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

NCT06278207
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (BAY 94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Phase 2 Study in Patients With MiT Tumors

NCT00557609
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS)
Interventions
ARQ 197
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
13 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
San Francisco, California • Santa Monica, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 24, 2026, 6:07 AM EDT
Completed No phase listed Observational

Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab

NCT00842699
View directory record Official record
Conditions
Renal Transplantation
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 24, 2026, 6:07 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

NCT00294502
View directory record Official record
Conditions
ESRD
Interventions
Gentamycin/citrate, Minocycline/EDTA
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

The Use of ACE Inhibitors in the Early Renal Post-transplant Period

NCT00270153
View directory record Official record
Conditions
Renal Transplant
Interventions
enalapril, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

NCT00372853
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
CP-675,206, SU011248
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Scottsdale, Arizona • New Brunswick, New Jersey • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Not applicable Interventional

The "Step4Life" Randomized Control Trial in Hemodialysis

NCT05241171
View directory record Official record
Conditions
Physical Activity, End Stage Kidney Disease, Hemodialysis
Interventions
Fitbit
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Explore Transplant @Home Within Kaiser Permanente Southern California

NCT03389932
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Patient-Guided
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

NCT05174221
View directory record Official record
Conditions
Kidney Disease, Glomerulonephritis
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Northridge, California • Nampa, Idaho • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

NCT06397872
View directory record Official record
Conditions
Renal Impairment
Interventions
100 mg Resmetirom Tablet
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

NCT04489771
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Miami, Florida • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

NCT01114672
View directory record Official record
Conditions
Pruritis
Interventions
50,000 Units Ergocalciferol, Placebo
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bethpage, New York • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 24, 2026, 6:07 AM EDT
Recruiting Phase 4 Interventional

Infliximab for Immune Checkpoint Inhibitor Associated AKI

NCT07683975
View directory record Official record
Conditions
Acute Kidney Injury, Acute Interstitial Nephritis
Interventions
Infliximab, Prednisone, prednisone (oral)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

NCT00244075
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplement, recombinant human growth hormone (rcGH), exercise
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 24, 2026, 6:07 AM EDT
Not yet recruiting Phase 2 Interventional

Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.

NCT07325201
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
Interventions
Sotagliflozin initiation
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 6:07 AM EDT
Terminated No phase listed Observational Results available

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

NCT02614898
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Eculizumab
Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 24, 2026, 6:07 AM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Mitochondria and Chronic Kidney Disease

NCT03177798
View directory record Official record
Conditions
Hemodialysis-Induced Symptom, Mitochondrial Diseases
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 78 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 24, 2026, 6:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

NCT01894906
View directory record Official record
Conditions
Kidney Failure
Interventions
Soluble Ferric Pyrophosphate, Placebo
Drug · Other
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 24, 2026, 6:07 AM EDT